Early cycle
Sleep-related changes are the earliest self-reports; they are anecdotal, not measured endpoints.
Protocol / Research Dosing Guide
Epithalon Dosage Guide: Reported Cycles, Reconstitution and Safety
An evidence-organized Epithalon (AEDG) guide that separates the synthetic tetrapeptide's cell and animal findings from the older pineal-extract human program, and keeps every reported schedule labeled as reported.
Last reviewed September 15, 202617 minute readResearch information only
Level 2 — Cell and animal evidenceNo blinded human trial of the synthetic peptideNot FDA approved
Epithalon Quick Start
Epithalon, also written epitalon, is a four–amino-acid synthetic peptide modeled on a pineal-gland extract. Laboratory work reports increased telomerase activity in human cell cultures, and rodent work reports lifespan and tumor-incidence effects. The strongest human numbers come from the natural extract epithalamin in non-blinded programs, not from the synthetic peptide.
Why researchers care
Telomere biology and circadian/melatonin rhythm research
Class
Synthetic tetrapeptide, Ala-Glu-Asp-Gly (AEDG)
Route reported
Subcutaneous use is reported; intranasal products exist without equivalence data
Cycle length
Short reported cycles spaced months apart; not trial validated
Regulatory status
Not FDA approved; sold research-use only
Loading supplier information
Epithalon Dosing Protocol and Schedule
The supplied coverage source describes two commonly repeated patterns: roughly 5 mg daily for 20 days, or roughly 10 mg daily for 10 days, each repeated two to three times per year with several months between cycles. These are reported patterns, not validated regimens.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Reported standard short cycle | 5 mg daily, evening, subcutaneous | 20 days, repeated 2–3 times per year |
| Reported condensed cycle | 10 mg daily, evening, subcutaneous | 10 days, repeated 2–3 times per year |
| Reported spacing | No amount | Cycles are reported 4–6 months apart |
No blinded human trial has tested a specific injected amount, cycle length, or repeat interval for the synthetic peptide. Both patterns above total roughly 100 mg per reported cycle.
Epithalon Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
Epithalon Reconstitution Calculator
Vial-format concentration math
Concentration
5 mg/mL
Draw volume
1 mL
U-100 units
100
Mathematical draws
2
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Epithalon: Morning or Night?
Morning or evening?
Reported protocols favor evening, reasoning from melatonin rhythm research on the extract. No trial has compared timing.
Daily or intermittent?
Reported use is once daily within a short cycle. Frequency is not experimentally established for the synthetic peptide.
With food?
Not applicable to an injected vial format and not established for any other format.
Missed amount?
No validated replacement or doubling procedure exists.
Epithalon Route Comparison
| Route | What is reported | Evidence limit |
|---|---|---|
| Subcutaneous | Nearly all reported community and legacy protocols | No modern controlled human dosing trial |
| Intranasal | Spray products are marketed | Absorption and equivalence are not established |
| Oral | Not established | No exposure data for the intact tetrapeptide |
| Route conversion | None available | Routes are not interchangeable |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Epithalon Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Circulating half-life | Reported to be very short, on the order of minutes | Typical for a tetrapeptide; no formal human PK publication was located |
| Duration of biological effect | Not established | Proposed gene-regulatory effects have not been measured in humans |
| Tissue distribution | Not established | No human distribution study |
| Frequency rationale | Short repeated cycles are reported | Not validated against an alternative schedule |
Epithalon Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 5 mg | Once daily for 20 days | Reported protocol | No |
| Subcutaneous | 10 mg | Once daily for 10 days | Reported protocol | No |
| Intranasal | Not established | Not established | Marketed format | No |
| Any route | Higher single amounts | Reported historically | No clearer reported outcome | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Epithalon Reconstitution Guide
Concentration: 5 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 5 mg | 1 mL | 100 units |
| 10 mg | 2 mL | 200 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Epithalon Works
Proposed telomere pathway
Cell-culture work reports increased telomerase activity and extended replicative lifespan in human fibroblasts.
Epithalon Human Trials and FDA Status
Current status · verified September 15, 2026
Not FDA approved; sold research-use only
- No double-blind randomized human trial of synthetic Epithalon was identified.
- Human cell-culture work reports telomerase activation and extended fibroblast division.
- Rodent work reports lifespan extension and lower spontaneous tumor incidence.
- Long-running non-blinded Russian programs report reduced mortality with the pineal extract epithalamin, often combined with a thymic peptide.
- A single published self-administration case report cannot establish an effect.
- Epithalon has no FDA-approved indication.
Who Should Avoid Epithalon?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data
Children or adolescents
No safety data
Active or prior cancer
Telomerase activation raises unresolved theoretical concerns
Concurrent medicines
No interaction studies
Immune or endocrine disorders
Effects on these systems are uncharacterized in humans
Long-term continuous use
Only short reported cycles exist; continuous safety is unknown
Epithalon Side Effects, Risks and Safety
Injection-site redness or sorenessReported
Important limitation: No controlled incidence data.
Drowsiness with evening useReported
Important limitation: Causality not established.
Allergic responseUnknown
Important limitation: No characterized safety dataset.
Telomerase-related theoretical riskTheoretical
Important limitation: No carcinogenicity study in humans.
Drug interactionsUnknown
Important limitation: No interaction studies.
Long-term effectsUnknown
Important limitation: No long-term human follow-up of the synthetic peptide.
Epithalon Timeline and Monitoring
During a reported cycle
No validated intermediate marker tracks Epithalon activity.
After a cycle
Any telomere or aging-marker change would be slow and only visible on laboratory testing.
Monitoring
No standard required panel exists. Telomere or biological-age panels are optional and debated.
Epithalon Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Telomere length or telomerase activity | Cell and animal evidence only | Human fibroblast cultures; rodent studies | No human outcome trial |
| Sleep or melatonin rhythm | Extract evidence only | Non-blinded elderly-subject extract studies | Does not transfer to the synthetic peptide |
| Mortality or lifespan | Extract evidence only | Non-blinded long-running programs | Not blinded, not replicated in the West |
| Tumor incidence | Animal evidence only | Rodent studies | No human anti-cancer claim is supported |
Epithalon Storage and Handling
Unreconstituted vial
Reported handling keeps the dry powder frozen, dry, and away from light; follow the exact product label.
Prepared vial
Reported handling refrigerates the solution and uses it within a short window; no validated stability study was located.
Freeze-thaw
Repeated freeze-thaw cycles of prepared solution are avoided in reported handling.
Appearance
Cloudiness, particles, or discoloration mean the material should not be used; clear appearance does not prove sterility.
Epithalon Troubleshooting
Numbers do not match another chart
Recheck vial milligrams, liquid volume, entered amount, and the U-100 conversion.
10 mg and 50 mg vials confused
The two sizes use different liquid volumes and different unit draws; recalculate from the exact label.
Solution looks cloudy
Stop and seek qualified product guidance; appearance cannot confirm sterility.
Extract evidence quoted as peptide evidence
Epithalamin studies are a separate body of work and do not validate the synthetic peptide.
A scheduled amount is missed
No validated missed-amount procedure exists.
Epithalon Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Epithalon (AEDG) | Synthetic tetrapeptide | Human cell cultures and rodent studies | Not approved |
| Epithalamin | Natural pineal extract | Non-blinded human programs | Not approved in the United States |
| MOTS-c | Mitochondrial-derived peptide | Largely preclinical | Not approved |
| NAD+ precursors | Cellular energy pathway | Preclinical plus early human work | Sold as supplements, not approved drugs |
Epithalon Frequently Asked Questions
What is Epithalon?
A synthetic four–amino-acid peptide (Ala-Glu-Asp-Gly) modeled on a pineal-gland extract, studied mainly in aging research.
Is Epithalon the same as epithalamin?
No. Epithalamin is a natural pineal extract; Epithalon is a synthetic tetrapeptide. Their evidence bases are separate.
Is it FDA approved?
No. It is sold research-use only.
Are there human trials of the synthetic peptide?
No blinded randomized human trial was identified.
What does the cell research report?
Increased telomerase activity and extended replicative lifespan in human fibroblast cultures.
What is the reported schedule?
Roughly 5 mg daily for 20 days, or 10 mg daily for 10 days, repeated a few times per year. This is reported, not validated.
What is its half-life?
Reported to be very short, on the order of minutes. No formal human pharmacokinetic publication was located.
Why is evening use reported?
Reported protocols reason from melatonin-rhythm findings on the extract. No trial has compared dosing times.
Does it treat or prevent cancer?
No. Rodent tumor-incidence findings do not support any human claim, and telomerase activation raises its own theoretical concerns.
What does the calculator do?
It converts entered vial and liquid values into concentration, draw volume, and U-100 unit arithmetic only.
Sources and Research
Coverage source
1. Epitalon protocol coverage source
Supplied coverage source for reported cycle patterns, handling, and information categories; not primary evidence.
Open direct sourceLaboratory research
2. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells
Human cell-culture study underpinning the telomere hypothesis; not a human outcome trial.
Open direct sourceAnimal research
3. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice
Rodent lifespan and tumor-incidence study; animal evidence only.
Open direct sourceRelated-compound human research
4. Geroprotective effect of epithalamine in elderly subjects with accelerated aging
Non-blinded human program using the pineal extract, not the synthetic peptide.
Open direct sourceMissing information flagged for review
- Blinded human trial of the synthetic peptide: Not established
- Human pharmacokinetics and half-life publication: Not established
- Validated human amount, cycle length, and repeat interval: Not established
- Intranasal absorption and route equivalence: Not established
- Long-term safety and carcinogenicity data: Not established
- Drug-interaction data: Not established